LeMaitre Vascular, Inc. (LMAT) Income Statement
LMAT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLMAT revenue and net income
Where LMAT's revenue goes
2025Each bar shows an amount and its share of revenue. LMAT kept 23.1% of revenue as net income.
LMAT profit margins
LMAT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +13.5% | +15.6% | +14.0% | +12.3% |
| Gross profit | +18.3% | +19.4% | +16.1% | +12.7% |
| Operating income | +30.0% | +36.3% | +18.7% | +19.4% |
| Net income | +31.1% | +40.9% | +22.2% | +22.2% |
| EPS (diluted) | +29.4% | +33.3% | +18.8% | +19.6% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LMAT quarterly EPS vs estimates
LeMaitre Vascular beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 4, 2026 (estimate $0.69).
LMAT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.6M | $219.9M | $193.5M | $161.7M | $154.4M | $129.4M | $117.2M | $105.6M | $100.9M | $89.2M |
| Cost of revenue | $71.1M | $69.0M | $66.4M | $56.8M | $53.0M | $44.7M | $37.4M | $31.6M | $30.2M | $26.2M |
| Gross profit | $178.5M | $150.9M | $127.0M | $104.9M | $101.4M | $84.6M | $79.9M | $73.9M | $70.7M | $62.9M |
| Research & development | $14.1M | $15.7M | $17.0M | $13.3M | $11.8M | $10.1M | $9.3M | $8.2M | $6.6M | $6.1M |
| Sales, general & admin | $96.5M | $83.0M | $72.9M | $61.7M | $53.2M | $46.2M | $49.4M | $45.0M | $43.0M | $40.5M |
| Total operating expenses | $110.6M | $98.6M | $90.3M | $78.1M | $65.0M | $55.8M | $58.7M | $53.2M | $49.6M | $46.6M |
| Operating income | $67.9M | $52.3M | $36.7M | $26.8M | $36.4M | $28.8M | $21.2M | $28.2M | $21.1M | $16.3M |
| Interest income | — | $4.9M | $2.5M | $986,000 | $197,000 | $207,000 | $698,000 | $631,000 | $179,000 | $81,000 |
| Interest expense | $5.2M | $205,000 | $0 | $986,000 | $2.2M | $1.3M | $5.9M | $2,000 | $21,000 | $14,000 |
| Income before taxes | $75.2M | $56.9M | $39.5M | $27.5M | $34.3M | $27.4M | $21.7M | $28.4M | $21.1M | $16.2M |
| Income taxes | $17.4M | $12.8M | $9.4M | $6.9M | $7.4M | $6.1M | $3.7M | $5.5M | $3.9M | $5.7M |
| Net income | $57.7M | $44.0M | $30.1M | $20.6M | $26.9M | $21.2M | $17.9M | $22.9M | $17.2M | $10.6M |
| EBITDA | $90.8M | $66.8M | $49.0M | $36.9M | $47.6M | $37.1M | $27.1M | $32.8M | $25.2M | $19.9M |
| EPS (diluted) | $2.51 | $1.94 | $1.35 | $1.06 | $1.26 | $1.06 | $0.88 | $0.80 | $0.85 | $0.55 |
| Gross margin | 71.5% | 68.6% | 65.7% | 64.9% | 65.7% | 65.4% | 68.1% | 70.0% | 70.1% | 70.6% |
| Operating margin | 27.2% | 23.8% | 19.0% | 16.6% | 23.6% | 22.3% | 18.1% | 26.7% | 20.9% | 18.3% |
| Net margin | 23.1% | 20.0% | 15.6% | 12.8% | 17.4% | 16.4% | 15.3% | 21.7% | 17.0% | 11.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.4M | $66.6M | $64.5M | $61.0M | $64.2M | $59.9M | $55.7M | $54.8M | $55.8M | $53.5M | $48.9M | $47.4M |
| Cost of revenue | $19.6M | $18.2M | $18.3M | $15.1M | $19.3M | $18.5M | $17.1M | $17.6M | $17.4M | $16.8M | $15.6M | $16.6M |
| Gross profit | $50.8M | $48.4M | $46.2M | $46.0M | $45.0M | $41.4M | $38.6M | $37.2M | $38.5M | $36.7M | $33.3M | $30.8M |
| Research & development | $4.8M | $4.1M | $3.5M | $3.0M | $3.5M | $4.1M | $3.6M | $3.7M | $4.3M | $4.1M | $4.4M | $4.2M |
| Sales, general & admin | $25.5M | $26.6M | $23.8M | $22.7M | $25.3M | $24.7M | $22.1M | $20.4M | $19.8M | $20.7M | $18.7M | $17.4M |
| Total operating expenses | $30.4M | $30.6M | $27.4M | $25.6M | $28.8M | $28.8M | $25.7M | $24.0M | $24.1M | $24.8M | $23.1M | $21.6M |
| Operating income | $20.4M | $17.8M | $18.8M | $20.3M | $16.1M | $12.6M | $12.9M | $13.1M | $14.4M | $11.9M | $10.2M | $9.2M |
| Interest income | $3.4M | — | — | $3.9M | $3.0M | $2.9M | $1.6M | $1.2M | $1.1M | $1.0M | $992,000 | $835,000 |
| Interest expense | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $205,000 | $0 | $0 | $1 | $143,000 | — |
| Income before taxes | $22.2M | $19.7M | $20.3M | $22.6M | $18.1M | $14.2M | $14.0M | $14.6M | $15.5M | $12.8M | $11.3M | $9.8M |
| Income taxes | $5.1M | $4.0M | $4.7M | $5.2M | $4.3M | $3.2M | $2.8M | $3.4M | $3.7M | $2.9M | $2.8M | $2.3M |
| Net income | $17.1M | $15.7M | $15.6M | $17.4M | $13.8M | $11.0M | $11.2M | $11.1M | $11.8M | $9.9M | $8.5M | $7.5M |
| EBITDA | $20.0M | $23.6M | $24.2M | $26.5M | $22.0M | $18.1M | $20.2M | $17.0M | $17.9M | $15.2M | $14.9M | $12.2M |
| EPS (diluted) | $0.74 | $0.68 | $0.68 | $0.75 | $0.60 | $0.48 | $0.49 | $0.49 | $0.52 | $0.44 | $0.38 | $0.33 |
| Gross margin | 72.1% | 72.7% | 71.7% | 75.3% | 70.0% | 69.2% | 69.3% | 67.8% | 68.9% | 68.6% | 68.1% | 65.0% |
| Operating margin | 29.0% | 26.7% | 29.2% | 33.3% | 25.1% | 21.1% | 23.1% | 24.0% | 25.7% | 22.2% | 20.9% | 19.4% |
| Net margin | 24.2% | 23.6% | 24.2% | 28.4% | 21.5% | 18.4% | 20.1% | 20.3% | 21.2% | 18.5% | 17.3% | 15.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LMAT's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LMAT financial results
In fiscal year 2025 (ended December 31, 2025), LeMaitre Vascular reported revenue of $249.6 million, up 13.5% from the year before. It had net income of $57.7 million (up 31.1%), a net profit margin of 23.1%. Diluted earnings per share came to $2.51. Over five years revenue grew at an average rate of 14.0% a year.
See the LMAT stock overview for the latest quote and news, or the LMAT chart for price history and technical indicators.
LMAT income statement FAQ
What is LeMaitre Vascular's annual revenue?
LeMaitre Vascular reported total revenue of $249.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 13.5% from $219.9 million the previous year.
Is LeMaitre Vascular profitable?
Yes. LeMaitre Vascular reported net income of $57.7 million in fiscal 2025, a net profit margin of 23.1%; its operating margin was 27.2%.
What is LeMaitre Vascular's gross margin?
LeMaitre Vascular's gross margin was 71.5% in fiscal 2025: for every $100 of revenue, LeMaitre Vascular kept $72 after the direct cost of its products and services.
How much does LeMaitre Vascular spend on research and development?
LeMaitre Vascular spent $14.1 million on research and development in fiscal 2025, 5.7% of revenue.
How fast is LeMaitre Vascular growing?
Revenue grew 14.0% a year on average over the last five fiscal years, from $129.4 million to $249.6 million.
What are LeMaitre Vascular's earnings per share?
LeMaitre Vascular earned $2.51 per diluted share in fiscal 2025, compared with $1.94 a year earlier.
When will LeMaitre Vascular report its next earnings?
LeMaitre Vascular is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does LeMaitre Vascular's fiscal year end?
LeMaitre Vascular's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.